February 2024 in “Veterinary sciences” Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.
June 2023 in “Current Issues in Molecular Biology” DN106212, an extract from a plant, is better at promoting hair growth than other tested substances by affecting hair growth factors and follicle development.
January 2017 in “Journal of Investigative Dermatology Symposium Proceedings” The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.
4 citations,
November 2023 in “Frontiers in immunology” New treatments targeting T-cell pathways are needed for better alopecia areata management.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
7 citations,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
7 citations,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
70 citations,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
September 2023 in “Frontiers in medicine” The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
6 citations,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
January 2016 in “Springer eBooks” Understanding drug interactions, side effects, and patient-specific factors is crucial for effective dermatological care.
36 citations,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
1 citations,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
1 citations,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.
August 2023 in “Dermatology and Therapy” Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
April 2024 in “Bioactive materials” New microneedle treatment with growth factors and a hair loss drug shows better and faster hair growth results than current treatments.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
2 citations,
March 2015 in “Expert opinion on orphan drugs” New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
1 citations,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
March 2024 in “Current issues in molecular biology” Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.
6 citations,
May 2022 in “Frontiers in physiology” Injecting CHIR-99021 into goose embryos improves feather growth by changing gene activity and energy processes.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
November 2023 in “Frontiers in pharmacology” Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.
1 citations,
June 2023 in “Dermatology and therapy” People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.